MedTrace Logo

Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00300222 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2008-03-06

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).

Conditions

  • Peripheral Nervous System Diseases
  • Pain
  • Neuralgia
  • Herpes Zoster
  • Shingles

Interventions

DRUG

NGX-4010

Sponsors & Collaborators

  • NeurogesX

    lead INDUSTRY

Principal Investigators

  • Jeffrey Tobias, MD · NeurogesX

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300222 on ClinicalTrials.gov